Hyperway Pharm is a growing and innovative pharmaceutical company specializing in the development of groundbreaking medicines. With a forward-thinking and international team of experts, the company stays abreast of global drug advancements and focuses on addressing patients' medication needs through innovation and independent research. Hyperway Pharm boasts a state-of-the-art research facility spanning over 2200 square meters, with more than 80% of its dedicated workforce being research professionals.

They have invested millions in cutting-edge equipment, establishing a unique brain-penetrating drug development platform, and have over 10 distinct pipelines for innovative drug research in urgent therapeutic areas such as tumor resistance, tumor immunology, pain management, central nervous system disorders, autoimmune diseases, and fungal infections. In just four years, Hyperway Pharm has applied for 26 invention patents, obtained seven authorizations, identified seven Preclinical Candidate Compounds (PCCs), and submitted four Investigational New Drug (IND) applications with three entering Phase I clinical trials. Several of their research achievements have received international recognition and have laid a solid foundation for their overseas expansion.

To ensure sustained innovation and value creation, Hyperway Pharm embraces a dual-drives strategy of innovation and collaboration. Leveraging their strengths in product pipeline layout, drug design, complex compound synthesis, and CMC research capabilities, they deepen partnerships and consolidate their R&D capacity. They are committed to nurturing a dynamic and enterprising research environment by continuously perfecting talent development strategies and incentives.

Guided by their corporate values of learning, innovation, goals, unity, love, and gratitude, Hyperway Pharm remains steadfast in their mission to develop conscientious medications that benefit patients worldwide